# Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in pMMR/MSS Locally Advanced Rectal Cancer

> **NCT07686640** · PHASE3 · RECRUITING · sponsor: **Shandong Cancer Hospital and Institute** · enrollment: 180 (estimated)

## Conditions studied

- Local Advanced Rectal Cancer
- Radiotherapy
- Immunotherapy

## Interventions

- **RADIATION:** Short-Course Radiotherapy
- **DRUG:** Consolidation treatment (With ICIs)
- **DRUG:** Consolidation treatment (Without ICIs)

## Key facts

- **NCT ID:** NCT07686640
- **Lead sponsor:** Shandong Cancer Hospital and Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-15
- **Primary completion:** 2029-07-15
- **Final completion:** 2030-07-15
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07686640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07686640, "Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in pMMR/MSS Locally Advanced Rectal Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07686640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*